NGENF (NervGen Pharma) ROE % Adjusted to Book Value : -9.92% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma ROE % Adjusted to Book Value?

NervGen Pharma's ROE % for the quarter that ended in Sep. 2024 was -194.26%. NervGen Pharma's PB Ratio for the quarter that ended in Sep. 2024 was 19.59. NervGen Pharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -9.92%.

NervGen Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for NervGen Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma ROE % Adjusted to Book Value Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-22.48

-14.52

-14.93

-18.80

NervGen Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-12.00	-	-13.80	-13.03	-9.92

Competitive Comparison of NervGen Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NervGen Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's ROE % Adjusted to Book Value falls into.

NervGen Pharma ROE % Adjusted to Book Value Calculation

NervGen Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-396.65%	/	N/A
	=	N/A

NervGen Pharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-194.26%	/	19.59
	=	-9.92%

NervGen Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

9UA:Germany NGEN:Canada

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

From GuruFocus

NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th

By PRNewswire PRNewswire • 07-09-2019